CollPlant's Vergenz Bio-Ink Shows High Success in Diabetic Foot Ulcer Trial
Ticker: CLGN · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1631487
Sentiment: bullish
Topics: biotechnology, medical-devices, clinical-trial, wound-care
TL;DR
CollPlant's Vergenz bio-ink healed 88% of diabetic foot ulcers in a trial, big win for wound care!
AI Summary
On October 20, 2025, CollPlant Biotechnologies Ltd. issued a press release announcing the successful completion of a clinical trial for its Vergenz™ rhCollagen-based bio-ink. The trial demonstrated significant improvements in wound healing for diabetic foot ulcers, with 88% of patients showing complete wound closure within 12 weeks. This positive outcome supports the potential of Vergenz™ as a novel therapeutic for chronic wound treatment.
Why It Matters
The successful trial results for Vergenz™ could lead to a new, effective treatment for diabetic foot ulcers, a condition with significant unmet medical needs and high healthcare costs.
Risk Assessment
Risk Level: medium — While the trial results are positive, the commercialization and regulatory approval process for new medical treatments carry inherent risks.
Key Numbers
- 88% — Complete Wound Closure (Achieved in patients treated with Vergenz™ for diabetic foot ulcers within 12 weeks.)
- 12 weeks — Treatment Duration (The timeframe within which complete wound closure was observed in the successful trial.)
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant and developer of Vergenz™
- Vergenz™ (product) — rhCollagen-based bio-ink used in the trial
- October 20, 2025 (date) — Date of press release
- diabetic foot ulcers (medical_condition) — Condition treated in the clinical trial
- 88% (percentage) — Percentage of patients with complete wound closure
- 12 weeks (duration) — Timeframe for complete wound closure
FAQ
What was the primary outcome of the clinical trial for CollPlant's Vergenz™ bio-ink?
The primary outcome was the demonstration of significant improvements in wound healing for diabetic foot ulcers, with 88% of patients achieving complete wound closure within 12 weeks.
What specific condition was treated in the clinical trial?
The clinical trial focused on treating diabetic foot ulcers.
What is Vergenz™?
Vergenz™ is CollPlant's rhCollagen-based bio-ink.
When was the press release regarding the trial results issued?
The press release was issued on October 20, 2025.
What percentage of patients achieved complete wound closure in the trial?
88% of patients achieved complete wound closure within 12 weeks.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2025-10-20 07:11:47
Filing Documents
- ea0261778-6k_collplant.htm (6-K) — 9KB
- ea026177801ex99-1_collplant.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-100133.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: October 20, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2